Jim Simons Taysha Gene Therapies, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$2.04 - $4.17 $586,296 - $1.2 Million	-287,400 Reduced 87.49%	41,100 $92,000
Q1 2024 May 13, 2024	SELL	$1.43 - $3.25 $1.1 Million - $2.5 Million	-768,900 Reduced 70.07%	328,500 $943,000
Q4 2023 Feb 13, 2024	BUY	$1.33 - $2.88 $664,202 - $1.44 Million	499,400 Added 83.51%	1,097,400 $1.94 Million
Q3 2023 Nov 14, 2023	BUY	$0.63 - $3.66 $235,368 - $1.37 Million	373,600 Added 166.49%	598,000 $1.89 Million
Q2 2023 Aug 11, 2023	SELL	$0.59 - $0.87 $14,868 - $21,924	-25,200 Reduced 10.1%	224,400 $148,000
Q1 2023 May 12, 2023	SELL	$0.65 - $2.3 $175,630 - $621,460	-270,200 Reduced 51.98%	249,600 $199,000
Q4 2022 Feb 13, 2023	BUY	$1.39 - $2.98 $140,807 - $301,874	101,300 Added 24.21%	519,800 $1.18 Million
Q3 2022 Nov 14, 2022	SELL	$1.76 - $4.94 $184,976 - $519,194	-105,100 Reduced 20.07%	418,500 $808,000
Q2 2022 Aug 12, 2022	BUY	$2.47 - $6.77 $674,557 - $1.85 Million	273,100 Added 109.02%	523,600 $1.95 Million
Q1 2022 May 13, 2022	BUY	$5.22 - $11.86 $1.31 Million - $2.97 Million	250,500 New	250,500 $1.63 Million

117

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $85.1M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.